NCT02003144 2022-08-23
An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc.
Guy's and St Thomas' NHS Foundation Trust
Office of Rare Diseases (ORD)